COVID-19 vaccination for hematopoietic stem cell transplant patients

The SARS-CoV-2 pandemic has changed the world over the last year and impacted almost every part of our lives. In particular,...

How can we use microbial-derived metabolites to prevent GvHD?

During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the GvHD Hub spoke to Erik Thiele...

NCCN COVID-19 vaccination recommendations for patients with hematologic malignancies

Patients with cancer are at high risk of COVID-19-associated complications and, accordingly, the preliminary...

Ruxolitinib fails to provide clinical benefit in patients with COVID-19-related cytokine storm

he efficacy and safety of adding ruxolitinib to standard of care (SoC) for patients with...

An overview of developments in reduced intensity conditioning and GvHD prophylaxis

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a treatment of choice for many hematologic...

What are the main challenges when evaluating novel agents for GvHD prophylaxis?

During the EHA2021 Virtual Congress, the GvHD Hub spoke with Robert Zeiser, Medical Center - University of Freiburg,...

Are you planning a phase II study of glasdegib in refractory sclerotic chronic GvHD?

During the EHA2021 Virtual Congress, the GvHD Hub spoke with Eduardo Rodriguez Arboli, University of Seville,...

Key communications on GvHD at EHA 2021

During the EHA2021 Virtual Congress, the GvHD Hub spoke with Mohamad Mohty, Hôpital Saint-Antoine, Paris, FR. We asked, What were the key communications on GvHD...

FDA approves belumosudil for the treatment of patients with cGvHD

On July 16, 2021, it was announced that the U.S. Food and Drug Administration (FDA) approved the use of belumosudil (200 mg once...

An overview of developments in reduced intensity conditioning and GvHD prophylaxis

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a treatment of choice for many hematologic...

Are you planning a phase II study of glasdegib in refractory sclerotic chronic GvHD?

During the EHA2021 Virtual Congress, the GvHD Hub spoke with Eduardo Rodriguez Arboli, University of Seville,...

Key communications on GvHD at EHA 2021

During the EHA2021 Virtual Congress, the GvHD Hub spoke with Mohamad Mohty, Hôpital Saint-Antoine, Paris, FR. We asked, What were the key communications on GvHD...